23 Jul, 2026
According to Straits Research the global nucleic acid amplification testing market size was valued at $10.5 billion in 2025 and is projected to grow from $11.36 billion in 2026 to $21.36 billion by 2034 at a CAGR of 8.21% during the forecast period 2026–2034.Nucleic acid amplification techniques, such as PCR (Polymerase Chain Reaction) and LAMP (Loop-mediated Isothermal Amplification), are powerful tools for amplifying specific DNA or RNA sequences. By making minute genetic material detectable, these techniques enable early diagnosis of diseases like COVID-19, HIV, and cancer, as well as genetic testing for hereditary conditions.
In addition to medical diagnostics, they play a crucial role in forensic science, helping identify individuals from small DNA samples. These technologies have revolutionized clinical diagnostics, research, and criminal investigations by ensuring accuracy and efficiency in detection.
Increasing prevalence of infectious diseases drives the global market
The growing prevalence of infectious diseases is a key factor driving the global nucleic acid amplification testing (NAAT) market, as the rising number of these diseases calls for accurate and rapid diagnostic solutions. Outbreaks of viral infections like COVID-19, influenza, and other respiratory diseases have particularly increased the demand for timely and reliable detection methods.
For example, the World Health Organization (WHO) reported in September 2023 that infectious diseases caused approximately 17 million deaths worldwide in 2022. This ongoing threat underscores the vital importance of nucleic acid amplification testing in managing and controlling diseases, fueling the market's growth.
Expansion of personalized medicine creates tremendous opportunities
The growth of personalized medicine presents a major opportunity for the global nucleic acid amplification testing (NAAT) market, as there is a rising demand for advanced diagnostic tools that provide precise genetic and molecular insights. NAAT allows for the identification of specific genetic markers linked to diseases, enabling the development of customized treatment plans that enhance patient outcomes.
For example, a 2023 report from the National Institutes of Health (NIH) revealed that nearly 75% of oncologists now use genetic testing to inform treatment decisions, demonstrating the increasing reliance on molecular diagnostics, like NAAT, in the field of personalized medicine. This trend highlights the vital role of the nucleic acid amplification testing market in advancing personalized healthcare and improving patient care.
North America is the largest shareholder in the global nucleic acid amplification market. This growth is driven by the increasing prevalence of infectious diseases and genetic disorders, along with rising demand for rapid diagnostic testing. The region's advanced healthcare infrastructure and significant investments in research and development further enhance market expansion.
sales@straitsresearch.com